Navigation Links
Eisai Joins Groundbreaking Tuberculosis Drug Accelerator Partnership to Discover New Tuberculosis Drugs
Date:11/25/2013

TOKYO, Nov. 25, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a groundbreaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB).

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

Jointly launched in June 2012 through a collaborative agreement among seven pharmaceutical companies1 and six research institutions2 with support from the Bill & Melinda Gates Foundation, the TBDA partnership targets the discovery of new TB drugs by working together on early-stage research. The long-term goal of the partnership is to create a new TB drug combination that has the potential to cure patients in only one month, compared to the six months of treatment required by existing drugs. Based on the partnership, the participating pharmaceutical companies will open up targeted sections of their compound libraries and share data with other participating pharmaceutical companies and research institutions. As a TBDA member, Eisai will provide selected portions of its chemical library for screening against TB as well as share identified and confirmed hits with other TBDA partners. Eisai will also work cooperatively with other partners to facilitate the development of new therapies for TB.

TB is a contagious disease caused by a bacterial infection that affects the lungs and other organs.  Although it is a curable and preventable disease, it is the second leading infectious cause of death worldwide, having resulted in the deaths of 1.4 million people in 2011 alone. One of the main reasons for the high mortality is that first-line therapies for TB are antiquated and inadequate, with all existing drugs being at least 50 years old and requiring at least six months to cure the disease. Furthermore, the length of the existing TB treatments means that a considerable number of patients drop out before completion, which in turn can lead to further transmission, emergence of drug resistance, and death. By discovering a new TB drug combination with the potential to cure patients in one month, the TBDA will contribute to shortening the length of treatment as well as decreasing treatment default rates.

Eisai is committed to improving the health and welfare of people in developing and emerging countries and considers its contributions to the economic development and expansion of the middle-income class through these endeavors as a form of long-term investment for future market growth. To achieve this, Eisai remains actively committed to addressing issues in global health to further increase the benefits provided to patients and their families worldwide.

1 AbbVie, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi

2 Infectious Disease Research Institute, National Institute of Allergy and Infectious Diseases, Rutgers University, Texas A&M University, University of Dundee, Weill Cornell Medical College

Media Inquiries:  
Public Relations Department,  
Eisai Co., Ltd.  
+81-(0)3-3817-5120

 

 


'/>"/>
SOURCE Eisai Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
2. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
3. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
4. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
5. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
6. FDA Grants Orphan Drug Status To Eisais Lenvatinib
7. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
8. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
9. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
10. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
11. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... NEW YORK , Dec. 6, 2016 ... atomic nucleus. Radioisotopes are produced either by using nuclear ... energy in the form of alpha, beta or gamma ... thus emitted are used in Nuclear medicine, specifically in ... to provide diagnostic information about a human body,s functioning. ...
(Date:12/6/2016)... 6, 2016 Human Vaccines Market: Scope ... wise and country wise analysis of the human ... of human vaccines products, raw material suppliers, vaccine ... the market. The report provides qualitative and ... Qualitative analysis comprises market dynamics, trends, product overview, ...
(Date:12/6/2016)... BOLTON, Miss. , Dec. 6, 2016 ... and rescue personnel in a simulated mass casualty event ... Mississippi . The technology debuted before an audience ... Bryant and representatives from Homeland Security, Federal Law ... Telemedical Drone Project, known as HiRO (Health Integrated Rescue ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... “Tomorrow Trump Goes ... Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes To ... do as much as she can for this country. , Nancy attributes her patriotic ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men ... a higher risk of serious health problems, such as cardiovascular illness, according to ... Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the correlation ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health management, announces today a strategic relationship with CitiusTech, a leading healthcare ... engine that offers advanced Clinical Quality Measures (CQM) computation capabilities (as a ...
(Date:12/6/2016)... ... December 06, 2016 , ... CarriersEdge, providers of online ... new suite of Driver Wellness courses. Offered in three modules, the courses can be ... so fleets can educate drivers about how to stay healthy on the road. , ...
Breaking Medicine News(10 mins):